

# References

## Fecal Microbiota Transplantation

1. Bartlett J G (2008) Historical perspectives on studies of *Clostridium difficile* and *C. difficile* infection. *Clin Infect Dis* **46**: S4–S11.
2. Aas J, Gessert C E, and Bakken J S (2003) Recurrent *Clostridium difficile* colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. *Clin Infect Dis* **35**: 580–585.
3. Heinlen L and Ballard J D (2010) *Clostridium difficile* infection. *Am J Med Sci* **340**(3): 247–252.
4. Gough E, Shaikh H, and Manges A R (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis* **53**(10): 994–1002.
5. Van Nood E, Speelman P, Kuijper E J, and Keller J J (2009) Struggling with recurrent *Clostridium difficile* infections: Is donor feces the solution? *Eurosurveillance* **14**(34): 1–6.
6. Brookshire B (May 18, 2018) To regulate fecal transplants, FDA has to first answer a serious question: What is poop? *Science News*; available from: <https://www.sciencenews.org/blog/scicurious/fecal-transplants-regulation>.
7. Ser H-L, Letchumanan V, Goh B-H, Wong S H, and Lee L-H (2021) The use of fecal microbiome transplant in treating human diseases: Too early for poop? *Front Microbiol* **12**: 519836, doi: 10.3389/fmicb.2021.519836; available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155486>.
8. Sasso J M, Ammar R M, Tenchov R, Lemmel S, Kelber O, Grieswelle M, and Zhou Q A (2023) Gut microbiome-brain alliance: a landscape view into mental and gastrointestinal health and disorders. *ACS Chem Neurosci* **14**: 1717–1763.
9. Feuerstadt P, Louie T J, Lashner B, Wang E E L, Diao L, Bryant J A, Sims M, Kraft C S, Cohen S H, Berenson C S, et al. (2022) SER-109, an oral microbiome therapy for recurrent *Clostridioides difficile* infection. *New Engl J Med* **386**(3): 220–229.
10. Borody T J, Warren E F, Leis S M, Surace R, Ashman O, and Siarakas S (2004) Bacteriotherapy using fecal flora: toying with human motions. *J Clin Gastroenterol* **38**(6): 475–483.
11. Mahobe R and Samal A (April 26, 2023) US FDA approves Seres Therapeutics' pill for deadly *C. difficile* infections. *Reuters*; available from: <https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-seres-therapeutics-pill-deadly-c-difficile-infections-2023-04-26>.
12. Rohlke F, Surawicz C M, and Stollman N (2010) Fecal flora reconstitution for recurrent *Clostridium difficile* infection: results and methodology. *J Clin Gastroenterol* **44**(8): 567–570.
13. Medical Letter (May 29, 2023) Live fecal microbiota oral capsules (Vowst) for prevention of CDI recurrence. *Medical Letter* **65**(1677): 81–82.
14. Van Nood E, Vireze A, Nieuwdorp M, Fuentes S, Zoetendal E G, De Vos W M, Visser C E, Kuijper E J, Bartelsman J F W M, Tijssen J G P, et al. (2013) Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *New Engl J Med* **368**(5): 407–415.
15. Youngster I, Russell G H, Pindar C, Ziv-Baran T, Sauk J, and Hohmann E L (2014) Oral, capsulized, frozen fecal microbiota transplantation for relapsing *Clostridium difficile* infection. *JAMA Network* **312**(17): 1772–1778.
16. Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan G G, Chang H-J, Coward S, Goodman K J, Xu H, et al. (2017) Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent *Clostridium difficile* infection. *JAMA* **318**(20): 1985–1993.
17. Medical Letter (March 6, 2023) Live fecal microbiota (Rebyota) for prevention of CDI recurrence. *Medical Letter* **65**(1671): 35–36.
18. Sheridan K and DeAngelis A (November 11, 2022) FDA approves first fecal microbiome drug, setting the stage for others. *Statnews.com*; available from: <https://www.statnews.com/2022/11/30/fda-approves-first-microbiome-drug/#:~:text=The%20Food%20and%20Drug.s%2C%20commonly%20known%20as%20C>.
19. Rossen N G, MacDonald J K, De Vries E M, D'Haens G R, De Vos W M, Zoetendal E G, and Ponsioen C Y (2015) Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. *World J Gastroenterol* **21**(17): 5359–5371.
20. Brogan J (November 4, 2016) Everyone poops. Some animals eat it. Why? *Smithsonian Magazine*; available from: <https://www.smithsonianmag.com/science-nature/everyone-poops-some-animals-eat-it-why-180961020>.
21. Lewin R A (2001) More on merde. *Perspect Biol Med* **44**(4): 594–607.
22. Garborg K, Waagsbø B, Stallermo A, Matre J, and Sundøy A (2010) Results of fecal donor instillation therapy for recurrent *Clostridium difficile*-associated diarrhea. *Scand J Infect Dis* **42**(11-12): 857–861.

## References: Fecal Microbiota Transplantation

23. Borody T J (2000) "Flora power"—Fecal bacteria cure chronic *C. difficile* diarrhea. *Am J Gastroenterol* **95**(11): 3028–3029.
24. Kahn M Y, Dirweesh A, Khurshid T L, and Siddiqui W J (2018) Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent *Clostridium difficile* infection: as systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* **30**(11): 1309–1317.
25. Hoffmann D, Palumbo F, Ravel J, Roghmann M-C, Rowthorn V, and Von Rosenvinge E (2017) Improving regulation of microbiota transplants. *Science* **358**(6369): 1390–1391.
26. FDA (November 2022) Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat *Clostridioides difficile* infection not responsive to standard therapies. Guidance for Industry; available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota>.
27. Kelly C R, Fischer M, Allegretti J R, LaPlante K, Stewart D B, Limketkai B N, and Stollman N H (2021) ACG clinical guidelines: Prevention, diagnosis, and treatment of *Clostridioides difficile* infections. *Am J Gastroenterol* **116**: 1124–1147.
28. Khanna S, Assi M, Lee C, Yoho D, Louis T, Knapple W, Aguilar H, Garcia-Diaz J, Wang G P, Berry S M, et al. (2022) Efficacy and safety of RBX2660 in PUNCH CD2, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent *Clostridioides difficile* infection. *Drugs* **82**: 1527–1538.
29. FDA (November 30, 2022) CBER Rebyota Summary Basis for Regulatory Action; available from: <https://www.fda.gov/media/163879/download>.
30. FDA April 26, 2023) CBER Vowst Summary Basis for Regulatory Action; available from: <https://www.fda.gov/media/168002/download>.
31. Cohen S H, Louie T J, Sims M, Wang E E L, Memisoglu A, McGovern B H, and Von Moltke L (2022) Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent *Clostridioides difficile* infection in a randomized clinical trial. *JAMA* **328**(2): 2062–2064.
32. Leong K S W, Jayasinghe T N, Wilson B C, Derraik J G B, Albert B B, Chiavaroli V, Svirskis D M, Beck K L, Conlon C A, Jiang Y, et al. (2020) Effects of fecal microbiome transfer in adolescents with obesity: the gut bugs randomized controlled trial. *JAMA Network Open* **3**(12):e2030415.

## Division Town Halls

### Connect and Network at ASPET's Division Town Halls

Join ASPET's town hall meetings to learn about the division's latest activities, including planned events for the ASPET 2024 Annual Meeting.

- Network with others who specialize in your research area.
- Connect with others who have a passion for pharmacology.
- Be inspired by the latest innovative science.

View the town hall schedule [here](#).

Discounts end April 18 to [register](#) for the annual meeting.